The Motley Fool Previous Page

Tomorrow's Monster Stock?

Rich Duprey
February 23, 2011

Stocks climbing to 10 times their original price are rare breeds -- but they're not impossible to find. Especially when you have Fools for friends.

The market's best stocks include companies that have risen dozens of times in value by taking advantage of the market's weaknesses. These aren't penny stocks; they're viable companies with sound business prospects that are achieving phenomenal returns. Finding just one or two of these monstrously successful firms can help you establish a winning portfolio.

Stalking the monster
To find tomorrow's winners, we've enlisted the help of more than 170,000 monster trackers at Motley Fool CAPS. We've compiled a list of the most successful CAPS members, dubbed All-Stars, whose picks have doubled, tripled, or even quadrupled in price. Then we've plucked out some of their recent picks for stocks they find equally promising.


CAPS Member Rating

Monster Stock

CAPS Score

Recent Stock Pick

CAPS Rating (out of 5)

cheev 96.54 ATP Oil & Gas 178.49 Anika Therapeutics (Nasdaq: ANIK  ) ****
Hibachi0 98.99 CNOOC 193.38 Plum Creek Timber (NYSE: PCL  ) *****
100ozRound 99.98 Ivanhoe Mines 765.45 Uranium Resources (Nasdaq: URRE  ) *****

Score is how many percentage points that pick is beating the S&P 500.

Of course, this is not a list of stocks to buy -- or, for those monster stocks that our CAPS All-Stars have already found, sell. Just consider them starting points for your own further research of extreme buying opportunities.

In search of bigfoot
Wires may have been crossed, but investors in Anika Therapeutics are paying the price. According to the therapeutic products developer, it was supposed to have a final site inspection of its Bedford, Mass., facilities completed by the Food and Drug Administration last December so it could move its manufacturing equipment in, but since the regulatory agency didn't take a look at it, it's now going to have to operate two sites until June of this year.

MannKind (Nasdaq: MNKD  ) also operated under the theory that the agency was going to consider its inhaled insulin treatment without any additional testing necessary, but that's just what happened, leaving some analysts to suggest the FDA had moved the goalposts on the biotech.

Anika also hasn't received a date for an FDA advisory panel meeting about the approval of Monovisc, a joint pain therapy it's developing. Assuming there aren't any more miscommunications, Anika expects the treatment will be approved.

CAPS member depletemycapital isn't so sure and blames mismanagement by the company for a series of mistakes that have occurred over the years.

Head over to the Anika Therapeutics CAPS page to weigh in yourself.

A forest full of lumber
It's not just homebuilders looking for a recovery in the housing industry. Forest management firm Plum Creek Timber and wood and paper products giant Weyerhaueser (NYSE: WY  ) would like to sell more lumber, and USG (NYSE: USG  ) wants to ship more wallboard. Although some see signs that a change may be coming with housing starts up almost 15% in January from the month before, I wouldn't hold my breath.